



500 Linden Oaks  
Rochester, New York 14625

## **VirtualScopics Receives Issuance in Japan of Prominent Patent**

ROCHESTER, NY – December 3, 2009 – VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of quantitative imaging for clinical trials, announced today that its patent titled “System and Method for 4D Reconstruction and Visualization” recently received issuance in Japan.

VirtualScopics’ Vice President of Technology and Product Development, Dr. Jonathan Riek, stated “We are pleased that Japan has recognized the uniqueness of VirtualScopics’ science by joining the United States, Germany, France, United Kingdom, and Israel in issuing this important patent.” He further added, “It is this patent which served as the basis for the formation of the company in 2000 and continues to set us apart among imaging providers today. We’ve been able to build upon this patent to specifically develop our musculoskeletal image analysis tools.” He concluded, “To date we’ve used these tools alone in over 90 musculoskeletal projects, assisting more than 15 leading pharmaceutical and medical device companies in the development of their drugs, devices and biologics.”

### **About VirtualScopics, Inc.**

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics’ industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit [www.virtualscopics.com](http://www.virtualscopics.com).

#####

### **Forward-Looking Statements**

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company’s investment in infrastructure and new customer contract signings and awards and/or statements preceded by, followed by or that include the words “believes,” “could,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “projects,” “seeks,” or similar expressions. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these

risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at [www.sec.gov](http://www.sec.gov). These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contract awards, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

**CONTACT:   Company Contact:**  
Molly Henderson  
Chief Business and Financial Officer  
500 Linden Oaks  
Rochester, New York 14625  
(585)249.6231